[go: up one dir, main page]

BR9912765A - Utilização de cloreto de sódio - Google Patents

Utilização de cloreto de sódio

Info

Publication number
BR9912765A
BR9912765A BR9912765-2A BR9912765A BR9912765A BR 9912765 A BR9912765 A BR 9912765A BR 9912765 A BR9912765 A BR 9912765A BR 9912765 A BR9912765 A BR 9912765A
Authority
BR
Brazil
Prior art keywords
sodium chloride
during
camptothecin
cancers
medication
Prior art date
Application number
BR9912765-2A
Other languages
English (en)
Inventor
Herve Toutain
Magali Guffroy
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Priority claimed from PCT/FR1999/001916 external-priority patent/WO2000007605A1/fr
Publication of BR9912765A publication Critical patent/BR9912765A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"UTILIZAçãO DE CLORETO DE SóDIO". Utilização de derivados da camptotecina para a preparação de medicamentos destinados aos tratamentos dos cânceres do trato gastrointestinal, provocando menores efeitos secundários gastrointestinais, caracterizada pelo fato de que uma solução de cloreto de sódio é administrada durante ou antes e durante a administração do referido medicamento.
BR9912765-2A 1998-08-05 1999-08-03 Utilização de cloreto de sódio BR9912765A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9810043A FR2782009B1 (fr) 1998-08-05 1998-08-05 Utilisation de derives de la comptothecine, avec une toxicite gastro-intestinale reduite
PCT/FR1999/001916 WO2000007605A1 (fr) 1998-08-05 1999-08-03 Utilisation de derives de la camptothecine, avec une toxicite gastro-intestinale reduite

Publications (1)

Publication Number Publication Date
BR9912765A true BR9912765A (pt) 2001-05-15

Family

ID=9529409

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9912765-2A BR9912765A (pt) 1998-08-05 1999-08-03 Utilização de cloreto de sódio

Country Status (6)

Country Link
CN (1) CN1144592C (pt)
BR (1) BR9912765A (pt)
FR (1) FR2782009B1 (pt)
PL (1) PL345826A1 (pt)
UA (1) UA72468C2 (pt)
YU (1) YU5301A (pt)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225404A (en) * 1989-11-06 1993-07-06 New York University Methods of treating colon tumors with tumor-inhibiting camptothecin compounds
WO1996011005A2 (en) * 1994-10-06 1996-04-18 Atlas Leon T Use of camptothecin or derivatives thereof for the manufacture of a medicament for the treatment of viral diseases

Also Published As

Publication number Publication date
PL345826A1 (en) 2002-01-14
FR2782009B1 (fr) 2000-09-15
CN1354667A (zh) 2002-06-19
UA72468C2 (en) 2005-03-15
CN1144592C (zh) 2004-04-07
FR2782009A1 (fr) 2000-02-11
YU5301A (sh) 2005-06-10

Similar Documents

Publication Publication Date Title
FI940787A0 (fi) Annostusmuoto lääkkeen annostelemiseksi lyhyessä ajanjaksossa
CY1105707T1 (el) Συνδυασμοι φορμοτερολης και ενος αλατος τριοτροπιου
BR122012014331A8 (pt) Formulações farmacêuticas
NO171145C (no) Fremgangsmaate for fremstilling av en fettemulsjon med et hydrofobt medikament
KR930007441A (ko) 의약품
KR920702216A (ko) 아세틸 d-카르니틴의 녹내장 치료에의 용도
CY1111088T1 (el) Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση
BR0015284A (pt) Formulações de hidrocodona de liberação controlada
NO306377B1 (no) Doseform for avgivelse av et medikament
CY1106727T1 (el) Ινδανυλ παραγωγα για την αντιμετωπιση ασθενειων αεραγωγων
IL81349A (en) Vinylphenol derivatives,their preparation and pharmaceutical compositions containing them
ES2053571T3 (es) Uso de propionato de fluticasona en la preparacion de una composicion farmaceutica para el tratamiento de enfermedades intestinales.
TR200101633T2 (tr) Farmasötik bileşim
BR9802537A (pt) Método para anestesiar um paciente humano antes de cirurgias de porte dose unitária e sistema farmacêutico para administração
BR9709838A (pt) Regime de administração que fornece um perfil de plasma no sangue de um inibidor de h+,k+-atpase composição farmacêutica oral uso da mesma e de inibidor h+,k+-atpase e processos para melhorar a inibição de secreção de ácido gástrico e o efeito terapêutico no tratamento de perturbações gastrintestinais e para receber um perfil estendido de plasma de um inibidor de h+,k+-atpase
SE9002500L (sv) Farmaceutisk, nac-innehaallande komposition foer oral administrering
GEP20043254B (en) Use of Camptothecin Derivatives with Reduced Gastrointestinal Toxicity
KR950013513A (ko) 약제 제조용 모에노마이신 및 이의 유도체, 및 모에노마이신 또는 이의 유도체를 함유하는 약제
SE8500996D0 (sv) Method of treatment
BR9912765A (pt) Utilização de cloreto de sódio
SE8705136D0 (sv) Oral doseringsenhet for lekemedel och dess anvendning och framstellning
HUP9802736A2 (hu) 1,4-Dihidropiridin-származékok alkalmazása artériafal ateroszklerózisos degradálódásának megelőzésére és gyógyítására alkalmas gyógyszerkészítmény előállítására
NZ514911A (en) Use of N-acetylcysteine for the preparation of a medicament suitable for the intravenous administration to prevent oxidative stress in dialysed patients
KR870009716A (ko) 클로르페니라민 제형
KR910004190A (ko) 온단세트론의 신규 의학 용도

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: PFIZER INC. (US)

Free format text: TRANSFERIDO DE: AVENTIS PHARMA S.A.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI